Onconic Therapeutics

Company Profile

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

N/A

Website

onconic.co.kr

Country

South Korea

Exchange

KOSDAQ

Founded 2020

Onconic Therapeutics provides the research and development of anti-cancer therapy in South Korea. It develops Zastaprazan (OCN-101), a potassium-competitive acid blocker, which is in phase 3 for the treatment of gastric acid related disease.

Its portfolio also includes OCN-201 (JPI-547), an anticancer drug, JP-1366, a treatment for peptic ulcer, and drugs for DDR and immuno-oncology fields. JP-1366, a poly ADP-ribose polymerase inhibitor, which is in phase 1 for the treatment of pancreatic cancer. Founded in 2020, the company is based in Seoul, South Korea.

Key Stats

52-Week Range

₩5662.50₩28900.00

BetaN/A

Trailing P/EN/A

Forward P/EN/A

Trailing EPSN/A

Avg Volume

Earnings & Analyst

Next EarningsN/A

EPS EstimateN/A

Target Mean PriceN/A

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.